文献速递类风湿关节炎

迈向最低有效剂量:多中心非劣效随机开放标签对照试验评估类风湿关节炎缓解期托珠单抗或阿巴西普注射间隔延长的结果

Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.
PubMed 文献 · Arthritis Rheumatol · 2024-01-25

这项多中心开放标签非劣效随机对照试验纳入233例持续缓解的已确诊类风湿关节炎患者,比较托珠单抗或阿巴西普全剂量维持与每3个月按DAS28驱动的渐进延长注射间隔至停药。按方案分析202例,主要终点DAS44斜率差0.10(95%CI 0.10-0.31),未证实非劣效;发作率和结构损伤进展率也均未证实非劣效。

要点

  • 延长间隔组16.2%停药、46.9%减量、36.9%恢复全剂量。
  • 主要终点DAS44斜率差0.10(95%CI 0.10-0.31),未证实非劣效。
  • 发作率差42.6%(95%CI 30.0-55.1),结构损伤进展率差13.9%(95%CI -6.7至34.4),均未证实非劣效。

核心结论

  • 该试验未能证实所提出的阿巴西普或托珠单抗减量策略的非劣效性。

研究设计与样本

  • 多中心开放标签非劣效随机临床试验,纳入233例接受稳定剂量阿巴西普或托珠单抗且持续缓解的已确诊类风湿关节炎患者,随机分为全剂量维持组和每3个月按DAS28驱动的渐进延长注射间隔组,主要终点为2年随访期间DAS44变化,按方案分析采用线性混合效应模型,基于斜率差单侧95%CI进行非劣效检验,非劣效界值0.25。

主要发现

  • 按方案分析共202例(延长间隔组90例,维持组112例)。
  • 随访结束时延长间隔组16.2%停用生物改善病情抗风湿药,46.9%减量,36.9%恢复全剂量。
  • 主要终点两组斜率差0.10(95%CI 0.10-0.31),未证实非劣效。
  • 发作率差42.6%(95%CI 30.0-55.1),未证实非劣效。
  • 2年结构损伤进展率差13.9%(95%CI -6.7至34.4),未证实非劣效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assess the clinical and structural impact at two years of progressively spacing tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in patients with rheumatoid arthritis in sustained remission. METHODS: This multicenter open-label noninferiority (NI) randomized clinical trial included patients with established rheumatoid arthritis in sustained remission receiving ABA or TCZ at a stable dose. Patients were randomized to treatment maintenance (M) at full dose (M-arm) or progressive injection spacing (S) driven by the Disease Activity Score in 28 joints every 3 months up to biologics discontinuation (S-arm). The primary end point was the evolution of disease activity according to the Disease Activity Score in 44 joints during the 2-year follow-up analyzed per protocol with a linear mixed-effects model, evaluated by an NI test based on the one-sided 95% confidence interval (95% CI) of the slope difference (NI margin 0.25). Other end points were flare incidence and structural damage progression. RESULTS: Overall, 202 of the 233 patients included were considered for per protocol analysis (90 in S-arm and 112 in M-arm). At the end of follow-up, 16.2% of the patients in the S-arm could discontinue their biologic disease-modifying antirheumatic drug, 46.9% tapered the dose and 36.9% returned to a full dose. NI was not demonstrated for the primary outcome, with a slope difference of 0.10 (95% CI 0.10-0.31) between the two arms. NI was not demonstrated for flare incidence (difference 42.6%, 95% CI 30.0-55.1) or rate of structural damage progression at two years (difference 13.9%, 95% CI -6.7 to 34.4). CONCLUSION: The Towards the Lowest Efficacious Dose trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kedra J, Dieudé P, Giboin C, et al. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission. Arthritis Rheumatol. 2024. PMID: 37942714. doi:10.1002/art.42752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。